Research study results‎ > ‎Generic‎ > ‎

Care Homes Independent Pharmacist Prescribing Study (CHIPPS)

Care Homes Independent Pharmacist Prescribing Study (CHIPPS): Experiences from a non‐randomised feasibility study. The aim of this study was to inform the definitive Randomised Controlled Trial (RCT). The results show that Pharmacist Independent Prescribers (PIPs) are valued by GPs, care home staff and residents but there are difficulties meeting care home staff and GPs due to service pressures, and the Pharmaceutical Care Plans are time consuming to complete. The protocol for the definitive RCT is being refined to addressed these issues, with recommendation that the PIPs have an existing working relationship with the GP. An abstract from oral presentation is published and can be accessed through International Journal of Pharmacy Practice

Care homes independent pharmacist prescribing study (CHIPPS): GP views on the potential role for pharmacist independent prescribers (PIPs) within care homes. This study aimed to determine GPs’ views on the utility and acceptability of PIPs. Focus groups and interviews involving 28 GPs were carried out in England, Scotland and Northern Ireland. Whilst GPs were largely supportive of PIPs assuming responsibility for repeat prescription management, there were concerns regarding the initiation of medication, and perceived implications for GP workload. The development of strong professional relationships and trust between the two professions is clearly required for the service to be successful. The article was published in InternationalJournal of Pharmacy Practice

Development of a core outcome set for effectiveness trials aimed at optimising prescribing in older adults in care homes. Prescribing medicines for older adults in care homes is known to be sub-optimal. The aim of this study was to develop a core outcome set (COS), a list of outcomes which should be measured and reported, as a minimum, for all effectiveness trials involving optimising prescribing in care homes. A long-list of 63 potential outcomes was identified and refined to 29 outcomes, which were included in the Delphi questionnaire (round 1). Following both rounds of the Delphi exercise, 13 outcomes (organised into seven overarching domains: medication appropriateness, adverse drug events, prescribing errors, falls, quality of life, all-cause mortality and admissions to hospital (and associated costs)) met the criteria for inclusion in the final COS. Widespread adoption of this COS will facilitate evidence synthesis between trials. The full open access publication can be accessed from Trials

Not just a ‘tick box exercise’ – meaningful public involvement in research. An article written by a long standing PPIREs member Kate Massey, who sadly died earlier this year. Kate gave her account on being a lay member on the management group of CHIPPS Programme and how the Public Involvement (PI) has been regarded as an integral element of the CHIPPS programme, where PI members have had ‘an effective equal partnership…, felt empowered and valued’ by the study team. The article is made permanently free to read in International Journal of Pharmacy Practice as a mark of respect for the author‘s long standing involvement in research.